Strategic Partnerships Genezen is actively expanding collaborations with biotech and gene therapy developers, evidenced by multiple high-profile partnerships in 2025 with Humane Genomics, Curebatten, and Optieum Biotechnologies. This presents a steady cadence of potential CDMO engagements for viral vector development and cGMP manufacturing.

Global Regulatory Footprint With a Lexington, MA site holding FDA, EMA, Health Canada, and MFDS Korea licenses and ongoing cGMP manufacturing in Indianapolis, Genezen offers multinational regulatory-ready capabilities that can accelerate late-stage programs and reduce time-to-market for partners seeking global trial and commercial manufacturing readiness.

Expanded TherapeuticFocus Genezen supports multiple vector modalities (AAV, lentiviral, retroviral) and is progressing programs across oncolytic virus therapy and CAR-T related constructs, including OPTF01. This diversity enables cross-selling opportunities across oncology and neurodegenerative spaces for both early-stage and mature programs.

Strong Employer Brand Recognition as a Great Place to Work and a BioSpace Best Places to Work winner in 2025 enhances recruiting and partner confidence, signaling a stable, employee-centric culture that can help sustain high-quality manufacturing capacity and reliable program execution for prospective clients.

Financial Capacity With annual revenue in the upper hundreds of millions and a development-friendly funding stature, Genezen has the financial scale to support multi-year, high-complexity manufacturing programs, offering potential clients reassurance on capacity, risk mitigation, and long-term collaboration viability.